Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient ...

Holdings announced that its supplemental new drug application, sNDA, of Gvoke VialDx has received U.S Food and Drug ...

Xeris Biopharma Holdings has received regulatory approval for a new use of its Gvoke liquid glucagon in gastrointestinal ...

We recently published a list of 12 Best Stocks to Invest in for a Stock Market Game. In this article, we are going to take a ...

InvestingPro analysis reveals 8 additional key insights about the company’s potential. Gvoke VialDx™ is designed to temporarily inhibit gastrointestinal movement during diagnostic procedures ...

Just in, Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) has received approval for its supplemental new drug application (sNDA) of Gvoke VialDx™ from the U.S. Food and Drug Administration (FDA).

Gvoke comes in three forms for subcutaneous injection: HypoPen auto-injector prefilled syringe prefilled vial and syringe kit To find out what the cost of Gvoke will be for you, talk with your ...

Key products include Gvoke for severe hypoglycemia, Keveyis for Primary Periodic Paralysis, and Recorlev for Cushing's Syndrome, with Recorlev showing strong growth. The company has a promising ...

The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the ...

Xeris also announced it has partnered with American Regent to commercialize Gvoke VialDx. Under the terms of the agreement, Xeris will be responsible for product supply, and American Regent will ...

CHICAGO - Xeris Biopharma Holdings, Inc. (NASDAQ: XERS), a $742 million market cap pharmaceutical company whose stock has surged 116% over the past year, has announced the FDA approval of its ...